Confo Therapeutics
Confo Therapeutics' unparalleled technology stabilizes functional conformations of GPCRs (G protein-coupled receptors) to uncover a wide range of previously inaccessible GPCRs as drug targets.
1
Funding Rounds
$33.6m
Money raised
Overview
Confo Therapeutics' unparalleled technology stabilizes functional conformations of GPCRs (G protein-coupled receptors) to uncover a wide range of previously inaccessible GPCRs as drug targets.
- Website:
- Business model: B2B
- Headquarters: Brussels
- Social accounts: linkedin
Funding series
Funding Series Analysis
The company Confo Therapeutics has raised a total of $33.6m in funding over 1 rounds.
Key Insights:
- Confo Therapeutics Series A round, May 2019: $33.6m
Confo Therapeutics Series A round, May 2019
$33.6m
Industries
Confo Therapeutics is active in the following industries: